A total of 219 R/R B-ALL patients who received CAR T-cell treatments were enrolled in our retrospective study, comprising 147 patients in the single CD19 group, 51 patients in the tandem CD19/CD22 group and 21 patients in the sequential CD19/CD22 group. This evidence concerns the gene CD22 and acute lymphoblastic leukemia.